Pfizer

U.S. FDA expands approval of HYMPAVZI for pediatric hemophilia A and B patients. Label now includes children as young as six, with and without inhibitors. First subcutaneous non factor therapy approved for hemophilia …

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a new…

Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built dividend portfol…

AMRX is expanding into GLP-1 manufacturing and biosimilars, using partnerships and acquisitions to strengthen its higher-value product strategy.

Pfizer wins FDA approval to expand Hympavzi's use in additional hemophilia A and B patient groups, including children with inhibitors.

Nurix (NRIX) stays a Strong Buy as bexobrutideg posts 83% ORR in r/r CLL and lands a $2.3B Roche deal—review the catalysts, risks, and outlook now.

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity pipeline.